Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening Software

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is excited to announce the development and launch of a new AI-powered software for high throughput salt and co-crystal screening – now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates.

This breakthrough technology streamlines solid form selection by minimizing trial and error experimentation, shortening development timelines, and lowering screening costs. With a user-friendly interface and advanced predictive models, the tool empowers clients to make smarter, data-driven decisions earlier in the drug substance development process —resulting in faster, more efficient delivery of optimized solid forms.

Eurofins CDMO Alphora’s seasoned Solid-State R&D team guides partners and customers through every stage of salt and co-crystal development—from data interpretation to experimental strategy. Beyond salt and co-crystal work, the team is well positioned to address a full spectrum of solid-state challenges. Through close cross-departmental collaboration with drug product and drug substance development teams, Eurofins CDMO Alphora delivers fully integrated solutions to improve therapeutic bioavailability and manufacturing processing.

To learn more, please visit: www.eurofins.com/cdmo

About Eurofins CDMO Alphora

Eurofins CDMO Alphora, part of an international network of Eurofins Scientific, develops and manufactures small molecule & biologic drug substances and drug products “under one roof” in Mississauga, Ontario, Canada. Our small molecule capabilities include the development and manufacture of API's and HPAPI's, oral drug products and API solid-state R&D. Our biologics capabilities include the development and manufacture of mAbs, proteins and ADCs, and Sterile Fill (2026). Established in 2003, our FDA, Health Canada, and Japan PMDA inspected site has over 250 people.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 65,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.